Virusga qarshi preparat

Vikipediya, ochiq ensiklopediya
Jump to navigation Jump to search

Virusga qarshi preparat virusli infeksiyalarni davolash uchun ishlatiladigan dorilar sinfidir.[1] Virusga qarshi preparatlarning aksariyati oʻziga xos viruslarga qarshi kurashadi, keng spektrli virusga qarshi preparatlar esa turli xil viruslarga qarshi taʼsir koʻrsatadi.[2] Aksariyat antibiotiklardan farqli oʻlaroq, virusga qarshi preparatlar maqsadli patogenini oʻldirmaydi; uning oʻrniga, uning rivojlanishiga toʻsqinlik qiladi.

Virusga qarshi preparatlar — bu antimikrobial preparatlarning bir sinfi boʻlib, antibiotiklarni (antibakterial preparatlar deb ham ataladi), antifungal va antiparazitik preparatlarni[3] yoki monoklonal antikorga asoslangan virusga qarshi preparatlarni oʻz ichiga olgan katta guruhdir.[4] Aksariyat virusga qarshi preparatlardan uy sharoida foydalanish uchun nisbatan zararsiz sanaladi, shuning uchun ham infeksiyalarni davolash uchun ishlatilishi mumkin. Bu turdagi preparat tana yoki uning tashqarisidagi virus zarralarini zararsizlantiradi yoki yoʻq qiladi. Tabiiy viritsidlar evkalipt va Avstraliyada uchraydigan choy daraxtlari kabi baʼzi oʻsimliklardan tayyorlanadi.[5]

Manbalar[tahrir]

  1. „Medmicro Chapter 52“. 18-Avgust 2000-yilda asl nusxadan arxivlandi. Qaraldi: 23-Yanvar 2021-yil.
  2. Rossignol JF (2014). "Nitazoxanide: a first-in-class broad-spectrum antiviral agent". Antiviral Res. 110: 94–103. doi:10.1016/j.antiviral.2014.07.014. PMID 25108173. PMC 7113776. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7113776. "Originally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identified as a first-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of influenza. ... From a chemical perspective, nitazoxanide is the scaffold for a new class of drugs called thiazolides. These small-molecule drugs target host-regulated processes involved in viral replication. ... A new dosage formulation of nitazoxanide is presently undergoing global Phase 3 clinical development for the treatment of influenza. Nitazoxanide inhibits a broad range of influenza A and B viruses including influenza A(pH1N1) and the avian A(H7N9) as well as viruses that are resistant to neuraminidase inhibitors. ... Nitazoxanide also inhibits the replication of a broad range of other RNA and DNA viruses including respiratory syncytial virus, parainfluenza, , rotavirus, norovirus, hepatitis B, hepatitis C, dengue, yellow fever, Japanese encephalitis virus and human immunodeficiency virus in cell culture assays. Clinical trials have indicated a potential role for thiazolides in treating rotavirus and norovirus gastroenteritis and chronic hepatitis B and chronic hepatitis C. Ongoing and future clinical development is focused on viral respiratory infections, viral gastroenteritis and emerging infections such as dengue fever." 
  3. "Pharmacology – Nursing Management", Contemporary Medical-Surgical Nursing. Cengage Learning, 2011 — s. 397. 
  4. Kisung Ko, Yoram Tekoah, Pauline M. Rudd, David J. Harvey, Raymond A. Dwek, Sergei Spitsin, Cathleen A. Hanlon, Charles Rupprecht, Bernhard Dietzschold, Maxim Golovkin, and Hilary Koprowski (2003). "Function and glycosylation of plant-derived antiviral monoclonal antibody". PNAS 100 (13): 8013–18. doi:10.1073/pnas.0832472100. PMID 12799460. PMC 164704. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=164704. 
  5. Schnitzler, P; Schön, K; Reichling, J (2001). "Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture". Die Pharmazie 56 (4): 343–47. PMID 11338678.